H.C. Wainwright maintains Buy rating on Dare Bioscience stock

On Thursday, H.C. Wainwright analysts reaffirmed their Buy rating for Dare Bioscience stock, maintaining a price target of $12.00. Currently trading at $3.10, the stock has shown strength with a 7.64% gain over the past week. According to InvestingPro data, analyst targets range from $12.00 to $14.00, suggesting significant upside potential. This decision follows an announcement from Dare Bioscience about a new partnership with Rosy Wellness, a women’s health app endorsed by over 8,000 healthcare professionals.

The collaboration aims to promote Dare Bioscience’s sildenafil cream, which is expected to be available in the fourth quarter of 2025. The company’s management highlighted this partnership as a significant step towards the commercialization of the product.

According to the analysts, Dare Bioscience plans to announce additional partners in the future to aid in the distribution and marketing of their products. The partnership with Rosy Wellness marks the initial phase of these efforts.

The analysts’ reaffirmation of the Buy rating and price target reflects their confidence in the company’s strategic direction and potential market impact of the sildenafil cream.

In other recent news, Daré Bioscience reported its financial results for the first quarter of 2025, highlighting a comprehensive loss of $4.4 million. The company is focusing on cost reduction and product innovation, including plans to launch four new products, such as the Sildenafil Cream and vaginal probiotics. Daré Bioscience aims to start generating revenue by the fourth quarter of 2025. Additionally, the company announced a strategic partnership with Rosy Wellness to promote the upcoming DARE to PLAY Sildenafil Cream, targeting female sexual arousal disorder. This collaboration will focus on educational outreach and digital support. The partnership aims to increase awareness among consumers and healthcare providers about the new product expected to be available by prescription in the United States in late 2025. Daré Bioscience also reduced its general and administrative expenses by 14% compared to the same period last year. The company is preparing to submit the Sildenafil Cream Phase III study by the second quarter of 2025, as part of its efforts to expand its product offerings in women’s health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.